This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
spike protein | 1023 |
respiratory syndrome | 716 |
binding domain | 596 |
syndrome coronavirus | 508 |
neutralizing antibodies | 503 |
receptor binding | 470 |
acute respiratory | 463 |
severe acute | 440 |
human ace | 407 |
spike glycoprotein | 379 |
amino acid | 313 |
middle east | 311 |
east respiratory | 305 |
cov rbd | 297 |
novel coronavirus | 282 |
coronavirus spike | 259 |
sars coronavirus | 250 |
converting enzyme | 248 |
neutralizing antibody | 243 |
cov spike | 229 |
monoclonal antibodies | 225 |
binding affinity | 215 |
ace receptor | 203 |
host cell | 198 |
monoclonal antibody | 183 |
author funder | 174 |
antibody responses | 173 |
immune responses | 172 |
convalescent plasma | 171 |
human monoclonal | 170 |
copyright holder | 169 |
amino acids | 169 |
viral entry | 169 |
immune response | 168 |
cov infection | 165 |
crystal structure | 165 |
granted medrxiv | 164 |
rbd protein | 162 |
binding site | 162 |
version posted | 161 |
cell entry | 160 |
ace binding | 155 |
room temperature | 152 |
spike proteins | 149 |
host cells | 138 |
doc id | 137 |
cord uid | 137 |
human coronavirus | 132 |
coronavirus disease | 132 |
kcal mol | 131 |
membrane fusion | 128 |
international license | 128 |
made available | 127 |
human igg | 125 |
structural basis | 125 |
antibody response | 123 |
rbd binding | 123 |
rbd domain | 122 |
em structure | 117 |
performed using | 113 |
antibody titers | 112 |
neutralizing activity | 110 |
rbd vaccine | 108 |
peer review | 104 |
rbd ace | 101 |
molecular dynamics | 101 |
receptor recognition | 100 |
viral infection | 100 |
wild type | 100 |
receptor ace | 99 |
fc ab | 98 |
cell surface | 98 |
potent neutralizing | 97 |
specific antibodies | 92 |
high affinity | 92 |
vaccine development | 90 |
highly conserved | 90 |
cell receptor | 90 |
binding interface | 89 |
fusion protein | 88 |
medrxiv preprint | 88 |
neutralization assay | 87 |
spike receptor | 86 |
hydrogen bonds | 86 |
previously described | 85 |
virus infection | 84 |
electron microscopy | 84 |
rights reserved | 84 |
cleavage site | 82 |
thermo fisher | 82 |
mg ml | 81 |
ace interaction | 78 |
influenza virus | 78 |
viral spike | 77 |
adjuvanted rbd | 76 |
free energy | 76 |
md simulations | 76 |
serum samples | 75 |
conformational changes | 75 |
tf tf | 72 |
negative control | 72 |
pdb id | 71 |
human cells | 70 |
virus entry | 70 |
flow cytometry | 70 |
serially diluted | 70 |
vaccine design | 69 |
rbd proteins | 69 |
convalescent subjects | 69 |
cell lines | 68 |
ge healthcare | 68 |
specific igg | 68 |
terminal domain | 68 |
cell culture | 67 |
prefusion conformation | 67 |
human neutralizing | 67 |
new coronavirus | 67 |
functional receptor | 66 |
ace complex | 65 |
binding domains | 65 |
coronavirus infection | 65 |
active site | 64 |
md simulation | 64 |
days post | 64 |
symptom onset | 63 |
mm nacl | 63 |
supplementary table | 63 |
subunit vaccine | 62 |
neutralization activity | 62 |
binding sites | 61 |
well plates | 61 |
human receptor | 61 |
glycosylation sites | 60 |
phage display | 60 |
viral rna | 60 |
igg fc | 60 |
specific antibody | 60 |
recombinant protein | 60 |
angiotensin converting | 59 |
type i | 59 |
disease severity | 59 |
antibody production | 59 |
ace orthologs | 58 |
potent neutralization | 58 |
protease inhibitor | 58 |
heavy chain | 58 |
neutralizing epitopes | 57 |
protective immunity | 57 |
spike rbd | 57 |
immune system | 57 |
cells expressing | 57 |
animal models | 57 |
three times | 56 |
ncov spike | 56 |
cell membrane | 56 |
goat anti | 56 |
structural analysis | 56 |
rbd igg | 56 |
surface area | 56 |
crystal structures | 56 |
neutralizing monoclonal | 56 |
severe covid | 55 |
class i | 55 |
acid residues | 55 |
dipeptidyl peptidase | 55 |
hot spot | 54 |
ic values | 54 |
protein rbd | 53 |
viral replication | 53 |
recombinant rbd | 53 |
antibodies targeting | 53 |
cell line | 52 |
cell fusion | 52 |
protein interactions | 52 |
domain complexed | 52 |
unexposed subjects | 52 |
neutralizing mabs | 52 |
transgenic mice | 51 |
fisher scientific | 51 |
per well | 51 |
respiratory tract | 51 |
antibody titer | 51 |
saudi arabia | 50 |
taken together | 50 |
hydrogen bond | 50 |
domain antibodies | 50 |
structural proteins | 50 |
sequence identity | 50 |
igg mbcs | 50 |
igg antibodies | 49 |
neutralize sars | 49 |
signal peptide | 49 |
clinical trials | 49 |
described previously | 49 |
binding motif | 49 |
public health | 48 |
innate immune | 48 |
ace isoforms | 48 |
vaccine candidate | 48 |
sequence alignment | 48 |
neutralization potency | 48 |
data bank | 48 |
target cells | 48 |
igg titers | 48 |
fc fusion | 47 |
structure determination | 46 |
graphpad prism | 46 |
mm tris | 46 |
authors declare | 46 |
protein data | 46 |
force field | 46 |
antibody binding | 45 |
virus neutralization | 45 |
protein binding | 45 |
viral fusion | 45 |
ace genes | 45 |
subunit vaccines | 45 |
entry depends | 45 |
plasma therapy | 44 |
molecular weight | 44 |
antibody levels | 44 |
based vaccines | 44 |
hydrophobic interactions | 44 |
ace protein | 44 |
posted august | 44 |
cov susceptibility | 44 |
exclusion chromatography | 43 |
clinically proven | 43 |
proven protease | 43 |
coronavirus receptor | 43 |
structural studies | 43 |
viral load | 43 |
fc protein | 43 |
fusion peptide | 43 |
domain iv | 43 |
results showed | 43 |
ace interface | 43 |
animal species | 42 |
igg levels | 42 |
biorxiv doi | 42 |
rbd complex | 42 |
closely related | 42 |
expression vector | 42 |
animal model | 42 |
previous studies | 42 |
highly potent | 41 |
ebola virus | 41 |
binding free | 41 |
bfe changes | 41 |
associated coronavirus | 41 |
length human | 41 |
ace expression | 41 |
mers coronavirus | 41 |
human coronaviruses | 41 |
domestic animals | 41 |
bat origin | 41 |
em structures | 40 |
human angiotensin | 40 |
side chain | 40 |
ace structure | 40 |
mouse model | 40 |
furin cleavage | 40 |
heparan sulfate | 39 |
positive selection | 39 |
hace receptor | 39 |
rbd antibody | 39 |
viral infections | 39 |
rbd residues | 39 |
cell responses | 39 |
epithelial cells | 39 |
mouse igg | 39 |
calculated using | 39 |
supplementary material | 39 |
ng ml | 39 |
serial dilutions | 38 |
without permission | 38 |
igg ab | 38 |
escape mutants | 38 |
water molecules | 38 |
results suggest | 38 |
secondary antibody | 38 |
reuse allowed | 38 |
host receptor | 38 |
mice immunized | 38 |
single domain | 38 |
allowed without | 38 |
bat coronavirus | 38 |
creative commons | 37 |
molecular docking | 37 |
humoral immune | 37 |
host immune | 37 |
ace receptors | 37 |
infectious diseases | 37 |
world health | 37 |
expression system | 37 |
results indicate | 37 |
convalescent individuals | 37 |
fusion proteins | 36 |
pneumonia outbreak | 36 |
spike ectodomain | 36 |
light chain | 36 |
two different | 36 |
human antibody | 36 |
neutralizing immunogenicity | 36 |
hydrogen bonding | 36 |
high levels | 36 |
binding affinities | 36 |
conformational dynamics | 36 |
significantly higher | 36 |
cov infections | 36 |
protein structure | 36 |
may also | 36 |
live virus | 36 |
binding assay | 36 |
health organization | 36 |
pseudovirus neutralization | 36 |
pseudotyped mers | 36 |
posted july | 36 |
domain bound | 36 |
like particles | 36 |
coronavirus associated | 35 |
infected cells | 35 |
binding region | 35 |
vero cells | 35 |
also observed | 35 |
rbd structure | 35 |
viral attachment | 35 |
patients infected | 35 |
acid sequence | 35 |
united states | 35 |
small molecules | 35 |
higher affinity | 35 |
novel human | 35 |
specific vhh | 35 |
trimeric spike | 35 |
recombinant sars | 35 |
hr domain | 35 |
soluble ace | 34 |
dynamics simulations | 34 |
rbd region | 34 |
previously reported | 34 |
probable bat | 34 |
heptad repeat | 34 |
well plate | 34 |
statistical significance | 34 |
important role | 34 |
cov strains | 34 |
sino biological | 33 |
plasmid encoding | 33 |
pseudotyped virus | 33 |
western blot | 33 |
sensor response | 33 |
control group | 33 |
sequence similarity | 33 |
civet ace | 33 |
cellular receptor | 33 |
immunized mice | 33 |
fold higher | 33 |
cp transfusion | 32 |
also found | 32 |
salt bridge | 32 |
rna viruses | 32 |
one rbd | 32 |
mg kg | 32 |
outbreak associated | 32 |
data collection | 32 |
culture medium | 32 |
polyclonal antibody | 32 |
using human | 32 |
rat ace | 32 |
dependent enhancement | 32 |
respiratory disease | 32 |
dromedary camels | 31 |
human cell | 31 |
plasmon resonance | 31 |
zebrafish larvae | 31 |
surface plasmon | 31 |
live sars | 31 |
secondary structure | 31 |
infected individuals | 31 |
negative controls | 31 |
electrostatic interactions | 31 |
extended data | 31 |
drug discovery | 31 |
clinical characteristics | 31 |
expression levels | 31 |
binding energy | 31 |
viral membrane | 30 |
conjugated anti | 30 |
vaccine candidates | 30 |
critical residues | 30 |
interacting residues | 30 |
viral proteins | 30 |
functional characterization | 30 |
inflammatory cytokines | 30 |
serum igg | 30 |
broadly neutralizing | 30 |
infected patients | 30 |
viral antigens | 30 |
glycosylation site | 30 |
protein complexes | 29 |
side chains | 29 |
protein interaction | 29 |
single inoculum | 29 |
molecular basis | 29 |
target protein | 29 |
glycoprotein rbd | 29 |
neutralization assays | 29 |
respiratory distress | 29 |
ace cells | 29 |
sialic acid | 29 |
protein expression | 29 |
spike glycoproteins | 29 |
bovine serum | 29 |
clinical features | 29 |
short ace | 29 |
coronavirus fusion | 29 |
linked immunosorbent | 29 |
mbcs reactive | 28 |
humoral immunity | 28 |
cells using | 28 |
van der | 28 |
cellular immune | 28 |
severe disease | 28 |
ic value | 28 |
tgev rbd | 28 |
size exclusion | 28 |
specific iga | 28 |
cell lysates | 28 |
porcine epidemic | 28 |
prefusion state | 28 |
neutralization titers | 28 |
data suggest | 28 |
recombinant proteins | 28 |
igg antibody | 28 |
cytopathic effect | 28 |
multiple sequence | 28 |
serological assay | 28 |
free energies | 27 |
affinity chromatography | 27 |
reactive igg | 27 |
ucsf chimera | 27 |
global health | 27 |
protein receptor | 27 |
neutralizing human | 27 |
respiratory syncytial | 27 |
washed three | 27 |
purified proteins | 27 |
analyzed using | 27 |
mouse sera | 27 |
human antibodies | 27 |
conformational change | 27 |
neutralizing activities | 27 |
binding pocket | 27 |
posted october | 27 |
measured using | 26 |
natural infection | 26 |
related coronavirus | 26 |
antiviral activity | 26 |
buffered saline | 26 |
fusion inhibitor | 26 |
web server | 26 |
small molecule | 26 |
serological tests | 26 |
igg response | 26 |
protective efficacy | 26 |
fatality rate | 26 |
viral infectivity | 26 |
healthy donors | 26 |
antibody library | 26 |
surface expression | 26 |
cov receptor | 26 |
protein folding | 26 |
higher binding | 26 |
syncytial virus | 26 |
single amino | 26 |
ace residues | 26 |
cov challenge | 26 |
deep mutational | 26 |
large number | 26 |
nucleocapsid protein | 26 |
specific human | 26 |
ncov rbd | 26 |
domain ii | 25 |
mammalian cells | 25 |
ill patients | 25 |
present study | 25 |
protease cleavage | 25 |
competing interests | 25 |
protein sequence | 25 |
highly specific | 25 |
positive control | 25 |
closed state | 25 |
glycan probe | 25 |
also showed | 25 |
inhibitory activity | 25 |
error bars | 25 |
statistically significant | 25 |
infectious virus | 25 |
rbd antibodies | 25 |
epidemic diarrhea | 25 |
respiratory coronavirus | 25 |
open state | 25 |
human dpp | 25 |
salt bridges | 25 |
sars cov | 25 |
human respiratory | 25 |
antibodies block | 25 |
human population | 25 |
purified using | 25 |
immune evasion | 24 |
receptorbinding domain | 24 |
conformational states | 24 |
rational design | 24 |
pseudotyped viruses | 24 |
key residues | 24 |
analysis based | 24 |
convalescent sera | 24 |
dependent manner | 24 |
detected using | 24 |
entry receptor | 24 |
therapeutic antibodies | 24 |
emc strain | 24 |
global pandemic | 24 |
recent studies | 24 |
adjuvant system | 24 |
dissociation constant | 24 |
immunosorbent assay | 24 |
adaptive immune | 24 |
epitope mapping | 24 |
coronavirus sars | 24 |
virus particles | 24 |
haddock score | 24 |
protein contains | 24 |
rbd domains | 24 |
standard deviation | 24 |
virus binding | 24 |
pathogenic coronaviruses | 24 |
antibodies elicited | 24 |
receptor dpp | 24 |
final concentration | 24 |
rbd antigen | 24 |
der waals | 24 |
targeting sars | 24 |
clinical trial | 24 |
wide range | 24 |
rhesus macaques | 24 |
acid substitutions | 24 |
recombinant mers | 24 |
total ig | 24 |
functional basis | 24 |
distress syndrome | 24 |
protein trimer | 23 |
positively charged | 23 |
exceptionally potent | 23 |
mm hepes | 23 |
linked glycans | 23 |
binding surface | 23 |
stranded rna | 23 |
hace complex | 23 |
western blotting | 23 |
ace blocking | 23 |
least two | 23 |
cov neutralizing | 23 |
iga antibodies | 23 |
phylogenetic analysis | 23 |
plasma transfusion | 23 |
accession number | 23 |
based vaccine | 23 |
receptor interactions | 23 |
binding residues | 23 |
viral envelope | 23 |
drug development | 23 |
rbd rasp | 23 |
hek cells | 23 |
spike trimer | 23 |
pseudovirus infection | 23 |
separate sites | 23 |
inhibit sars | 23 |
related coronaviruses | 23 |
fusion state | 23 |
rbd i | 23 |
ace gene | 23 |
uncaria tomentosa | 23 |
buried surface | 23 |
highly pathogenic | 23 |
recombinant receptor | 23 |
least one | 23 |
prevent sars | 23 |
two distinct | 23 |
docking studies | 23 |
loaded onto | 23 |
binding kinetics | 23 |
live mers | 23 |
cov antibody | 23 |
critically ill | 23 |
hospitalized patients | 23 |
full length | 23 |
coronavirus entry | 23 |
recent study | 23 |
complex structure | 23 |
different epitopes | 23 |
culture supernatant | 23 |
transfected cells | 22 |
significantly reduced | 22 |
per mouse | 22 |
current study | 22 |
assay using | 22 |
receptor usage | 22 |
virtual screening | 22 |
cov entry | 22 |
ace variants | 22 |
neg species | 22 |
cell epitopes | 22 |
rna virus | 22 |
elisa plates | 22 |
cd cd | 22 |
antibody therapies | 22 |
transiently transfected | 22 |
coronavirus infections | 22 |
complete genome | 22 |
supporting information | 22 |
cryptic epitope | 22 |
ns protein | 22 |
similar results | 22 |
asymmetric unit | 22 |
cp therapy | 22 |
mm imidazole | 22 |
hot spots | 22 |
diarrhea virus | 22 |
viral rbd | 22 |
trimer cavity | 22 |
generated using | 22 |
high titers | 22 |
protein induces | 22 |
confirmed cases | 22 |
molecular graphics | 22 |
human sars | 22 |
fc domain | 22 |
antibody neutralization | 21 |
plate reader | 21 |
tissue culture | 21 |
lung tissue | 21 |
neutralization test | 21 |
combinatorial adjuvant | 21 |
virus fusion | 21 |
cov pseudovirus | 21 |
fetal bovine | 21 |
high specificity | 21 |
viral protein | 21 |
peptide inhibitors | 21 |
fusion core | 21 |
new york | 21 |
serine protease | 21 |
health care | 21 |
protein binds | 21 |
genome sequence | 21 |
human serum | 21 |
purified rbd | 21 |
intact ace | 21 |
potent sars | 21 |
protein concentration | 21 |
prefusion spike | 21 |
antigenic sites | 21 |
conformational state | 21 |
diagnostic accuracy | 21 |
passive transfer | 21 |
culture supernatants | 21 |
angiotensinconverting enzyme | 21 |
induce neutralizing | 21 |
igg production | 21 |
plasma membrane | 21 |
viral surface | 21 |
homology modelling | 21 |
mouse ace | 21 |
membrane protein | 21 |
igm antibodies | 21 |
rna polymerase | 21 |
serological assays | 21 |
previous reports | 21 |
protein structures | 21 |
results demonstrate | 20 |
ligand binding | 20 |
synthetic nanobodies | 20 |
rbd interaction | 20 |
outer membrane | 20 |
significant increase | 20 |
cell membranes | 20 |
glycoproteins reveal | 20 |
spike antigen | 20 |
independent experiments | 20 |
human fc | 20 |
luciferase activity | 20 |
three rbds | 20 |
molecular replacement | 20 |
significantly lower | 20 |
pdb code | 20 |
reactive mbcs | 20 |
protein production | 20 |
dynamic receptor | 20 |
statistical analysis | 20 |
diffraction data | 20 |
conserved cryptic | 20 |
within days | 20 |
cell attachment | 20 |
determined using | 20 |
vaccinia virus | 20 |
human mabs | 20 |
virus challenge | 20 |
residues involved | 20 |
molar ratio | 20 |
recombinant ace | 20 |
pbs containing | 20 |
bd biosciences | 20 |
fc tag | 20 |
cellular immunity | 20 |
human transmission | 20 |
immune cells | 20 |
domain antibody | 20 |
plasma donors | 20 |
may provide | 20 |
low levels | 20 |
avian influenza | 20 |
emerging human | 19 |
protein efficiently | 19 |
significant difference | 19 |
competitive biopanning | 19 |
data indicate | 19 |
binding activity | 19 |
small animal | 19 |
dpp binding | 19 |
fusion inhibition | 19 |
nucleic acid | 19 |
potent cross | 19 |
based design | 19 |
see methods | 19 |
high binding | 19 |
long structural | 19 |
mouse serum | 19 |
optical density | 19 |
elisa assay | 19 |
way anova | 19 |
lower respiratory | 19 |
blocking sars | 19 |
biotinylated rbd | 19 |
type rbd | 19 |
cells ml | 19 |
protein complex | 19 |
therapeutic agents | 19 |
ns md | 19 |
elisa assays | 19 |
fold increase | 19 |
major target | 19 |
tg mice | 19 |
acid fragment | 19 |
palm civets | 19 |
two proteins | 19 |
patient samples | 19 |
papn ectodomain | 19 |
gel filtration | 19 |
escherichia coli | 19 |
i ifn | 19 |
exposed subjects | 19 |
protective immune | 19 |
confirmed covid | 19 |
data analysis | 19 |
light chains | 19 |
isolated rbd | 19 |
south korea | 18 |
viral particles | 18 |
hr domains | 18 |
smd simulations | 18 |
therapeutic development | 18 |
expression plasmid | 18 |
rbd core | 18 |
lung injury | 18 |
mammalian cell | 18 |
stably transfected | 18 |
envelope protein | 18 |
potent binding | 18 |
human mab | 18 |
purifying selection | 18 |
previously shown | 18 |
corona virus | 18 |
sars patients | 18 |
care workers | 18 |
statistical analyses | 18 |
like coronavirus | 18 |
docking results | 18 |
binding energies | 18 |
two independent | 18 |
epitopes within | 18 |
host range | 18 |
immune enhancement | 18 |
incubated overnight | 18 |
sd domain | 18 |
like protease | 18 |
linked glycosylation | 18 |
body weight | 18 |
currently available | 18 |
cho cell | 18 |
time rt | 18 |
major livestock | 18 |
rbd complexes | 18 |
blood type | 18 |
energy landscape | 18 |
glycan shield | 18 |
plaque assay | 18 |
reduced binding | 18 |
therapeutic potential | 18 |
cov virus | 18 |
receptor interaction | 18 |
serum albumin | 18 |
ace antibody | 18 |
binding model | 18 |
biolayer interferometry | 18 |
fusion inhibitors | 18 |
viral genome | 18 |
lymph nodes | 18 |
specific neutralizing | 18 |
one hour | 18 |
commons license | 18 |
using graphpad | 17 |
bei resources | 17 |
significantly different | 17 |
viral loads | 17 |
mass spectrometry | 17 |
interaction interface | 17 |
entry inhibitors | 17 |
membrane vesicles | 17 |
rbd mutants | 17 |
two subunits | 17 |
fully human | 17 |
transcription factors | 17 |
vaccine antigen | 17 |
genome sequences | 17 |
determine whether | 17 |
random coils | 17 |
bat sars | 17 |
coronavirus nl | 17 |
rbd surface | 17 |
deep mutagenesis | 17 |
total igg | 17 |
transmissible gastroenteritis | 17 |
coronavirus mers | 17 |
cov vaccine | 17 |
structure analysis | 17 |
protein ectodomain | 17 |
binding mode | 17 |
inflammatory responses | 17 |
chain variable | 17 |
cell immunity | 17 |
human immunodeficiency | 17 |
binding epitope | 17 |
escape mutations | 17 |
variable domain | 17 |
igg responses | 17 |
plaque reduction | 17 |
san diego | 17 |
standard biopanning | 17 |
mutational scanning | 17 |
weight loss | 17 |
effective vaccine | 17 |
rationally designed | 17 |
closed conformation | 17 |
infection rate | 17 |
immunodeficiency virus | 17 |
host cellular | 17 |
serum sample | 17 |
mortality rate | 17 |
specific igm | 17 |
drug repurposing | 17 |
relatively low | 17 |
bound ace | 17 |
rbd using | 17 |
bind sars | 17 |
bat coronaviruses | 17 |
antibody detection | 17 |
affinity maturation | 17 |
life cycle | 17 |
systematic review | 17 |
binding assays | 17 |
structural insights | 17 |
recombinant human | 17 |
enveloped viruses | 17 |
ng well | 17 |
tightly closed | 17 |
post infection | 17 |
binding loops | 16 |
antibody titres | 16 |
significant differences | 16 |
among different | 16 |
recovered patients | 16 |
rbd fusion | 16 |
peripheral blood | 16 |
virus replication | 16 |
coronavirus spikes | 16 |
based assays | 16 |
target proteins | 16 |
severe cases | 16 |
posted june | 16 |
rbd bound | 16 |
hcl ph | 16 |
protein concentrations | 16 |
critical role | 16 |
rbd alone | 16 |
strong neutralizing | 16 |
designed prefusion | 16 |
upward rbd | 16 |
highly similar | 16 |
emergency use | 16 |
rna binding | 16 |
proteolytic cleavage | 16 |
convalescent patients | 16 |
expressing human | 16 |
coronavirus vaccine | 16 |
pathogenic coronavirus | 16 |
nta resin | 16 |
main protease | 16 |
study showed | 16 |
binding efficiency | 16 |
cell receptors | 16 |
tbs ph | 16 |
dpp receptor | 16 |
disulfide bonds | 16 |
protein variants | 16 |
prefusion mers | 16 |
rbd epitopes | 16 |
three rbd | 16 |
potential therapeutic | 16 |
soluble human | 16 |
antibody concentration | 16 |
different concentrations | 16 |
clinical outcomes | 16 |
lg ml | 16 |
i interferon | 16 |
complex formation | 16 |
ray crystal | 16 |
also used | 16 |
sars vaccines | 16 |
reduction neutralization | 16 |
detect sars | 16 |
host ace | 16 |
dependent rna | 16 |
various concentrations | 16 |
viral antigen | 16 |
negative bfe | 16 |
endoplasmic reticulum | 16 |
cells via | 16 |
viral clearance | 16 |
day post | 16 |
serum antibody | 16 |
biosafety level | 16 |
receptor angiotensin | 16 |
different viral | 16 |
analysis showed | 16 |
serum dilution | 16 |
horseradish peroxidase | 16 |
life technologies | 16 |
binding epitopes | 16 |
antibody libraries | 16 |
protein docking | 16 |
diluted mouse | 15 |
hospitalized covid | 15 |
gel electrophoresis | 15 |
spike gene | 15 |
several studies | 15 |
high performance | 15 |
proximal promoter | 15 |
apoplastic fluid | 15 |
blocking antibodies | 15 |
cov ratg | 15 |
open conformation | 15 |
results show | 15 |
conserved among | 15 |
terminal human | 15 |
washed times | 15 |
neutralization titer | 15 |
engineered decoy | 15 |
adult zebrafish | 15 |
acute lung | 15 |
glycoprotein reveal | 15 |
key target | 15 |
glycoprotein receptor | 15 |
length sars | 15 |
molecular dynamic | 15 |
patient sera | 15 |
antiviral drug | 15 |
infectious disease | 15 |
data show | 15 |
urgently needed | 15 |
pg mm | 15 |
dna vaccine | 15 |
first step | 15 |
acid pairs | 15 |
plasma samples | 15 |
functional assessment | 15 |
blocking buffer | 15 |
ec value | 15 |
mesh ewald | 15 |
conjugated goat | 15 |
cytoplasmic tail | 15 |
specific binding | 15 |
host proteases | 15 |
critical amino | 15 |
time points | 15 |
conformation structure | 15 |
living cells | 15 |
also demonstrated | 15 |
charged residues | 15 |
fractions containing | 15 |
hong kong | 15 |
time step | 15 |
rbd immunized | 15 |
polyclonal antibodies | 15 |
direct binding | 15 |
findings suggest | 15 |
livestock species | 15 |
see table | 15 |
i virus | 15 |
end point | 15 |
autodock vina | 15 |
source data | 15 |
highly immunogenic | 15 |
length spike | 15 |
cell response | 15 |
scoring function | 15 |
microscopy structures | 15 |
cell types | 15 |
tested positive | 15 |
virus spike | 15 |
therapeutic efficacy | 15 |
including sars | 15 |
serological testing | 15 |
much lower | 15 |
interface residues | 15 |
immobilized ace | 15 |
based assay | 15 |
antiviral therapeutics | 15 |
ace molecules | 15 |
viral neutralization | 15 |
fr nps | 15 |
next day | 15 |
fusion spike | 15 |
terminal region | 15 |
reactive antibodies | 15 |
risk factors | 15 |
prerequisite conformational | 15 |
hr region | 15 |
informed consent | 14 |
neutralizes sars | 14 |
lysis buffer | 14 |
rabbit anti | 14 |
potency index | 14 |
long ace | 14 |
protease tmprss | 14 |
antibody cocktail | 14 |
mediates viral | 14 |
dengue virus | 14 |
results obtained | 14 |
homology modeling | 14 |
sequence analysis | 14 |
viral subunit | 14 |
antibody blocking | 14 |
ace molecule | 14 |
two mutations | 14 |
dependent cellular | 14 |
fusion conformation | 14 |
selective pressure | 14 |
simulation time | 14 |
potent human | 14 |
estrogen molecules | 14 |
viral determinants | 14 |
molecular modeling | 14 |
potential drug | 14 |
another study | 14 |
inhibitor targeting | 14 |
respiratory infections | 14 |
neutralizing nanobodies | 14 |
thermo scientific | 14 |
intensive care | 14 |
first reported | 14 |
general population | 14 |
isre stat | 14 |
large scale | 14 |
homology model | 14 |
cov antibodies | 14 |
coronavirus hku | 14 |
cell viability | 14 |
electrochemical anodization | 14 |
insect cells | 14 |
interaction energy | 14 |
direct elisa | 14 |
negatively charged | 14 |
better understand | 14 |
coronavirus vaccines | 14 |
pcr positive | 14 |
binding specificity | 14 |
inhibitors targeting | 14 |
innate immunity | 14 |
top lead | 14 |
reporter gene | 14 |
sera collected | 14 |
af mab | 14 |
vesicular stomatitis | 14 |
macromolecular structure | 14 |
em data | 14 |
limited number | 14 |
reactive mbc | 14 |
postexposure efficacy | 14 |
chain antibodies | 14 |
medium containing | 14 |
susceptible species | 14 |
nisin variants | 14 |
effective vaccines | 14 |
free rbd | 14 |
cohort study | 14 |
visualized using | 14 |
two weeks | 14 |
antibody concentrations | 14 |
electrochemical detection | 14 |
cells well | 14 |
specific monoclonal | 14 |
huh cells | 14 |
spike pseudotyped | 14 |
higher levels | 14 |
sa protein | 14 |
nta affinity | 14 |
positive clones | 14 |
using elisa | 14 |
treat covid | 14 |
steepest descent | 14 |
small size | 14 |
disulfide bond | 14 |
dg bind | 14 |
human sera | 14 |
neutralization activities | 14 |
decoy receptors | 14 |
humoral response | 14 |
intermediate hosts | 14 |
viral receptor | 14 |
alexa fluor | 14 |
affinity binding | 14 |
high sequence | 14 |
supplementary information | 14 |
common cold | 14 |
rbd mabs | 14 |
hace binding | 14 |
genomic characterization | 14 |
inactivated sars | 14 |
emerging viruses | 13 |
hdpp receptor | 13 |
plasma recipients | 13 |
close proximity | 13 |
binding strength | 13 |
posted may | 13 |
data set | 13 |
antibodies directed | 13 |
cells per | 13 |
core complex | 13 |
medical center | 13 |
mammalian expression | 13 |
type sars | 13 |
naturally occurring | 13 |
cell sorting | 13 |
dynamics simulation | 13 |
promoter regions | 13 |
block covid | 13 |
virus type | 13 |
derived peptides | 13 |
case fatality | 13 |
kindly provided | 13 |
trimeric sars | 13 |
authentic sars | 13 |
cr fab | 13 |
particle mesh | 13 |
chain reaction | 13 |
therapeutic strategies | 13 |
lymph node | 13 |
mediated neutralization | 13 |
spike antibody | 13 |
serum levels | 13 |
like cleavage | 13 |
neutralized sars | 13 |
antiviral agents | 13 |
mediated immunity | 13 |
reverse transcription | 13 |
also known | 13 |
reverse genetics | 13 |
signal peptides | 13 |
newly identified | 13 |
right panel | 13 |
polymerase chain | 13 |
coding sequence | 13 |
malayan pangolins | 13 |
likely due | 13 |
expressing cells | 13 |
widely used | 13 |
molecular simulations | 13 |
directed mutagenesis | 13 |
spot region | 13 |
even though | 13 |
positive results | 13 |
commons attribution | 13 |
protein expressed | 13 |
million confirmed | 13 |
pangolin coronavirus | 13 |
bind ace | 13 |
potential therapy | 13 |
extracellular domain | 13 |
sequence homology | 13 |
posted september | 13 |
two separate | 13 |
fda approved | 13 |
mouse anti | 13 |
three days | 13 |
antiviral drugs | 13 |
target cell | 13 |
significant role | 13 |
related viruses | 13 |
hydrogen atoms | 13 |
efficiently binds | 13 |
igg igg | 13 |
pseudovirus entry | 13 |
yeast surface | 13 |
viral vector | 13 |
expressed recombinant | 13 |
serial dilution | 13 |
ab levels | 13 |
transition state | 13 |
hbs buffer | 13 |
expi cells | 13 |
structural protein | 13 |
epitope containing | 13 |
veroe cells | 13 |
rapid development | 13 |
rbd mutations | 13 |
cell memory | 13 |
genbank accession | 13 |
reference strain | 13 |
cov binding | 13 |
binding antibodies | 13 |
conformational transition | 13 |
ace proteins | 13 |
wash buffer | 13 |
biopanning strategy | 13 |
ligand interactions | 13 |
cp treatment | 13 |
plasmids encoding | 13 |
cov vaccines | 13 |
interfacial contacts | 13 |
type ii | 13 |
important target | 13 |
bind simultaneously | 13 |
signal sequence | 13 |
control groups | 13 |
interaction energies | 13 |
three weeks | 13 |
strong binding | 13 |
cell sequencing | 13 |
using different | 13 |
key role | 13 |
mean square | 13 |
immune sera | 13 |
using sars | 13 |
reference ssaa | 13 |
receptor cd | 13 |
uncaric acid | 13 |
large conformational | 13 |
increases infectivity | 13 |
antibody tests | 13 |
cov rbds | 13 |
lung tissues | 13 |
causative agent | 13 |
cho cells | 13 |
analysis revealed | 13 |
rbd variants | 13 |
neutralizing titers | 13 |
noncompeting pair | 13 |
analysis using | 13 |
transient expression | 13 |
coronavirus isolates | 13 |
cov neutralization | 13 |
aligned using | 13 |
standard deviations | 13 |
relatively high | 13 |
dark blue | 13 |
pcr test | 13 |
mice received | 13 |
rbd may | 13 |
chromatography using | 12 |
rbm region | 12 |
luciferase reporter | 12 |
virus control | 12 |
different animal | 12 |
slightly higher | 12 |
specific target | 12 |
comparative elisa | 12 |
broad range | 12 |
conformational epitopes | 12 |
mucosal immunity | 12 |
three independent | 12 |
class ii | 12 |
influenza hemagglutinin | 12 |
microscopy structure | 12 |
molecular mechanisms | 12 |
postfusion state | 12 |
purified protein | 12 |
receptor association | 12 |
pixel size | 12 |
median age | 12 |
ground prefusion | 12 |
drug targets | 12 |
soluble expression | 12 |
influenza viruses | 12 |
rbd sera | 12 |
gene expression | 12 |
fold dilutions | 12 |
iga levels | 12 |
species transmission | 12 |
rbd binds | 12 |
cr epitope | 12 |
adcho cells | 12 |
entry assay | 12 |
hydrophobic pocket | 12 |
zinc ion | 12 |
two groups | 12 |
human primates | 12 |
vaccine efficacy | 12 |
ace bound | 12 |
molecular orbital | 12 |
highly effective | 12 |
structural characterization | 12 |
inhibition assay | 12 |
throughput screening | 12 |
virus origins | 12 |
surface protein | 12 |
adapted sars | 12 |
ad hdpp | 12 |
neutralizing mab | 12 |
virus disease | 12 |
control mice | 12 |
crystal violet | 12 |
competitive binding | 12 |
liquid nitrogen | 12 |
sera samples | 12 |
induces protective | 12 |
fresh medium | 12 |
conjugated secondary | 12 |
surface receptor | 12 |
display antibody | 12 |
convergent antibody | 12 |
based subunit | 12 |
rbd vaccines | 12 |
rapid detection | 12 |
root mean | 12 |
recombinant spike | 12 |
virus titers | 12 |
sars virus | 12 |
block interaction | 12 |
results also | 12 |
assays using | 12 |
female balb | 12 |
preliminary report | 12 |
humanized mice | 12 |
binding inhibition | 12 |
convalescent sars | 12 |
ab binding | 12 |
targeting antibodies | 12 |
strong correlation | 12 |
protein sequences | 12 |
host membranes | 12 |
elisa plate | 12 |
angiotensin system | 12 |
antiviral peptides | 12 |
point titers | 12 |
potential inhibitor | 12 |
variable domains | 12 |
four structural | 12 |
conformational masking | 12 |
crucial role | 12 |
based system | 12 |
newly emerged | 12 |
olfactory organ | 12 |
ssaa ligand | 12 |
fold serial | 12 |
based peptide | 12 |
elicit neutralizing | 12 |
pedv strains | 12 |
fc region | 12 |
descriptive study | 12 |
open access | 12 |
antibody fragments | 12 |
human proteins | 12 |
well elisa | 12 |
potential vaccine | 12 |
solution containing | 12 |
contact residues | 12 |
magnetic beads | 12 |
prcv rbd | 12 |
human dipeptidyl | 12 |
incipient wetting | 12 |
electron microscope | 12 |
structural similarity | 12 |
molecule inhibitors | 12 |
two viruses | 12 |
high concentration | 12 |
mediated cell | 12 |
drug target | 12 |
decoy receptor | 12 |
od value | 12 |
monoclonal sars | 12 |
neutralising antibody | 12 |
two major | 12 |
showed high | 12 |
sialic acids | 12 |
specific humoral | 12 |
like coronaviruses | 12 |
ig variants | 12 |
intermediate host | 12 |
unexposed individuals | 12 |
predicted model | 12 |
last ns | 12 |
bind rbd | 12 |
antibody combination | 12 |
commercially available | 12 |
animals including | 12 |
transmembrane domain | 12 |
may help | 12 |
block sars | 12 |
standard curve | 12 |
results provide | 12 |
stomatitis virus | 12 |
coronavirus structural | 12 |
site asn | 12 |
ter meulen | 12 |
also performed | 11 |
quantified using | 11 |
mice serum | 11 |
high degree | 11 |
pandemic influenza | 11 |
migratory monocytes | 11 |
essential role | 11 |
three distinct | 11 |
npt ensemble | 11 |
specific mabs | 11 |
neutralising activity | 11 |
disease onset | 11 |
virus hemagglutinin | 11 |
bacterial expression | 11 |
within rbd | 11 |
continuous variables | 11 |
peptide rbd | 11 |
antigenic epitopes | 11 |
inhibits mers | 11 |
disease pathogenesis | 11 |
cleavage sites | 11 |
lower affinity | 11 |
maxisorp plates | 11 |
blocking receptor | 11 |
health emergency | 11 |
data table | 11 |
comparative protein | 11 |
correlation analysis | 11 |
model surfaces | 11 |
contains multiple | 11 |
sex hormones | 11 |
visualization system | 11 |
shell domain | 11 |
infection generates | 11 |
left panel | 11 |
levels wane | 11 |
structure solution | 11 |
conditioned medium | 11 |
biological sex | 11 |
bound rbd | 11 |
virus strains | 11 |
response time | 11 |
throughput single | 11 |
virus evolution | 11 |
result showed | 11 |
recently described | 11 |
coronavirus attachment | 11 |
functional analysis | 11 |
rbd specific | 11 |
chain rbd | 11 |
ct value | 11 |
posted april | 11 |
coronavirus pneumonia | 11 |
synergistic effect | 11 |
energy calculations | 11 |
mouse hepatitis | 11 |
comprehensive python | 11 |
neutralisation activity | 11 |
syrian hamsters | 11 |
viral titer | 11 |
attachment inhibitor | 11 |
vaccine platform | 11 |
using protein | 11 |
helix bundle | 11 |
viral shedding | 11 |
sars vaccine | 11 |
dilution series | 11 |
rrbd protein | 11 |
rbd antigens | 11 |
slightly lower | 11 |
studies revealed | 11 |
hrp conjugated | 11 |
vaccinated mice | 11 |
catalytic site | 11 |
genomic characterisation | 11 |
sars pseudovirus | 11 |
domain i | 11 |
containing rbd | 11 |
containing mm | 11 |
fold dilution | 11 |
rbd interface | 11 |
aspartic acid | 11 |
catalytic activity | 11 |
bound state | 11 |
contacting residues | 11 |
lethal mers | 11 |
binding protein | 11 |
nd immunization | 11 |
epitope binning | 11 |
nucleic acids | 11 |
type receptor | 11 |
cov uses | 11 |
current pandemic | 11 |
antibodies using | 11 |
structural features | 11 |
enzyme receptor | 11 |
different spike | 11 |
glycoprotein trimer | 11 |
rbd binders | 11 |
much less | 11 |
exploratory research | 11 |
antibodies binding | 11 |
samples collected | 11 |
glycan probes | 11 |
effectively inhibit | 11 |
molecular biology | 11 |
mm edta | 11 |
acid residue | 11 |
receptor protein | 11 |
binding modes | 11 |
human tissues | 11 |
biological replicates | 11 |
significantly decreased | 11 |
ff sb | 11 |
recently reported | 11 |
angiotensin i | 11 |
health concern | 11 |
cells transfected | 11 |
antibody recognition | 11 |
collected days | 11 |
endothelial cells | 11 |
coronavirus adaptation | 11 |
following sars | 11 |
virus ns | 11 |
urgent need | 11 |
cd cells | 11 |
amicon ultra | 11 |
protects human | 11 |
peptidase domain | 11 |
nm nm | 11 |
protein may | 11 |
inhibitory concentration | 11 |
descent algorithm | 11 |
gastroenteritis virus | 11 |
nasal swabs | 11 |
also detected | 11 |
inflammatory mediators | 11 |
coronavirus ratg | 11 |
approved drugs | 11 |
assay results | 11 |
hepatitis virus | 11 |
first time | 11 |
electron density | 11 |
rbd showed | 11 |
molecular simulation | 11 |
observations suggest | 11 |
antibodies specific | 11 |
like sars | 11 |
distinct epitopes | 11 |
drug resistance | 11 |
protein genes | 11 |
candidate vaccine | 11 |
envelope glycoprotein | 11 |
dual route | 11 |
homotrimeric spike | 11 |
ab bound | 11 |
infectious bronchitis | 11 |
upper respiratory | 11 |
igg binding | 11 |
norovirus shell | 11 |
igg concentrations | 11 |
trachea tissue | 11 |
inflammatory response | 11 |
study also | 11 |
influenza vaccine | 11 |
hours post | 11 |
dependent neutralizing | 11 |
energy minimization | 11 |
sigma aldrich | 11 |
hace protein | 11 |
antibody escape | 10 |
treating covid | 10 |
significant correlation | 10 |
virus clearance | 10 |
cell population | 10 |
dynamic simulations | 10 |
hcov oc | 10 |
developing sars | 10 |
protein bound | 10 |
highly stable | 10 |
ace structural | 10 |
sequence variation | 10 |
potential target | 10 |
also called | 10 |
well maxisorp | 10 |
full spike | 10 |
dendritic cells | 10 |
antibody assays | 10 |
ec values | 10 |
using anti | 10 |
mild disease | 10 |
overall neutralizing | 10 |
mdck cells | 10 |
range electrostatic | 10 |
induce specific | 10 |
human cd | 10 |
ace inhibitor | 10 |
constructed using | 10 |
affinity antibodies | 10 |
specific ctfh | 10 |
cellular entry | 10 |
ethics committee | 10 |
mutant rbd | 10 |
effective antiviral | 10 |
least days | 10 |
ramachandran plot | 10 |
graphics system | 10 |
three different | 10 |
previously identified | 10 |
fragment molecular | 10 |
chain contacts | 10 |
neutralizing response | 10 |
changes induced | 10 |
antiviral innate | 10 |
human heavy | 10 |
ti sheet | 10 |
building tools | 10 |
human polyclonal | 10 |
mild covid | 10 |
md snapshots | 10 |
surface papn | 10 |
blood donation | 10 |
based drug | 10 |
multiple comparisons | 10 |
fully glycosylated | 10 |
production process | 10 |
antibodies bound | 10 |
conserved receptor | 10 |
electrostatic potential | 10 |
coronavirus hcov | 10 |
natural variants | 10 |
coated overnight | 10 |
extended loops | 10 |
also tested | 10 |
image processing | 10 |
genome sequencing | 10 |
multimeric rbd | 10 |
entry mechanisms | 10 |
sequence data | 10 |
expression plasmids | 10 |
herpes simplex | 10 |
free medium | 10 |
buffer containing | 10 |
coronavirus isolated | 10 |
sensor surface | 10 |
palm civet | 10 |
docking scores | 10 |
drug design | 10 |
normal mode | 10 |
tertiary structure | 10 |
allowed us | 10 |
low level | 10 |
will need | 10 |
supplemental table | 10 |
protein using | 10 |
antigen binding | 10 |
mutation rates | 10 |
fluorescence intensity | 10 |
antigenic structure | 10 |
loop region | 10 |
recently emerged | 10 |
activated cell | 10 |
pathogenic human | 10 |
double mutations | 10 |
rapid generation | 10 |
determining regions | 10 |
tris ph | 10 |
molecular mechanism | 10 |
rbd mf | 10 |
density map | 10 |
antibody cr | 10 |
reciprocal ic | 10 |
binding competition | 10 |
fusion structure | 10 |
data sets | 10 |
novel therapeutic | 10 |
immunogenetic diversity | 10 |
syrian hamster | 10 |
virus neutralizing | 10 |
weeks post | 10 |
specific nbs | 10 |
small number | 10 |
also show | 10 |
block receptor | 10 |
time pcr | 10 |
aromatic residues | 10 |
porcine respiratory | 10 |
antibody protects | 10 |
double mutants | 10 |
hydrophobic residues | 10 |
without antibody | 10 |
negative selection | 10 |
showed similar | 10 |
organ failure | 10 |
equal volume | 10 |
reactive neutralization | 10 |
immune escape | 10 |
induce highly | 10 |
vaccine formulation | 10 |
plasma treatment | 10 |
protein containing | 10 |
heptad repeats | 10 |
fc mf | 10 |
angiotensin ii | 10 |
clinical symptoms | 10 |
protein also | 10 |
soluble ectodomain | 10 |
mhc class | 10 |
cell expression | 10 |
density maps | 10 |
quality control | 10 |
infect humans | 10 |
might also | 10 |
conventional antibodies | 10 |
antibody fragment | 10 |
light scattering | 10 |
concentration range | 10 |
severe respiratory | 10 |
block ace | 10 |
saliva samples | 10 |
acid changes | 10 |
closed structure | 10 |
good agreement | 10 |
human airway | 10 |
healthcare workers | 10 |
new sars | 10 |
em analysis | 10 |
four different | 10 |
rbd sequences | 10 |
antibody targets | 10 |
flow rate | 10 |
cell adhesion | 10 |
domain camelid | 10 |
pos species | 10 |
expression vectors | 10 |
binding ability | 10 |
receptor expression | 10 |
high potency | 10 |
two rbds | 10 |
ifn response | 10 |
contacting network | 10 |
plasmid dna | 10 |
using two | 10 |
media containing | 10 |
nod signaling | 10 |
southern china | 10 |
vertebrate species | 10 |
causes severe | 10 |
rp patients | 10 |
therapeutic targets | 10 |
coronavirus oc | 10 |
sprotein rbd | 10 |
probably due | 10 |
also suggest | 10 |
pcov gx | 10 |
phylogenetic tree | 10 |
polyclonal sera | 10 |
surface display | 10 |
obtained using | 10 |
convalescent phase | 10 |
immunodominant non | 10 |
subunit contains | 10 |
mbc formation | 10 |
tissues using | 10 |
iga abs | 10 |
evolutionary dynamics | 10 |
investigate whether | 10 |
five times | 10 |
engineered human | 10 |
part number | 10 |
novel sars | 10 |
species severe | 10 |
sequence encoding | 10 |
induces strong | 10 |
initial model | 10 |
blood donors | 10 |
data points | 10 |
different time | 10 |
igg isotype | 10 |
cov ntd | 10 |
mice immunised | 10 |
soluble aggregates | 10 |
functionalized tio | 10 |
data processing | 10 |
virus vaccine | 10 |
type sace | 10 |
coronavirus isolate | 10 |
significantly increased | 10 |
clinical course | 10 |
acid substitution | 10 |
viral diseases | 10 |
first round | 10 |
fmo results | 10 |
major antigenic | 10 |
inactivated vaccine | 10 |
original author | 10 |
wild animals | 10 |
entry efficiency | 10 |
i viral | 10 |
controlled trial | 10 |
studies showed | 10 |
rbd within | 10 |
layer interferometry | 10 |
higher anti | 10 |
two functional | 10 |
rbd residue | 10 |
time point | 10 |
papn rbd | 10 |
monomeric rbd | 10 |
affinity towards | 10 |
epi isl | 10 |
reducing conditions | 10 |
mutant hdpp | 9 |
single dose | 9 |
terminal helix | 9 |
grade soluble | 9 |
bridge interaction | 9 |
neutralization antibodies | 9 |
mimicry elucidates | 9 |
phase i | 9 |
mutational scan | 9 |
missing residues | 9 |
initial docking | 9 |
human anti | 9 |
high capacity | 9 |
simultaneous binding | 9 |
quantitative real | 9 |
analysis suggests | 9 |
specific residues | 9 |
receptor complex | 9 |
unexpected receptor | 9 |
preprint server | 9 |
virus infectivity | 9 |
much higher | 9 |
catalytic domain | 9 |
embryonic kidney | 9 |
synergistic effects | 9 |
alanine scanning | 9 |
golden syrian | 9 |
human primate | 9 |
elucidates activation | 9 |
nonhospitalized cases | 9 |
mechanical ventilation | 9 |
targeting rbd | 9 |
gene encoding | 9 |
cells treated | 9 |
rbm residues | 9 |
competition assay | 9 |
one day | 9 |
two complexes | 9 |
mutant proteins | 9 |
disease progression | 9 |
pymol molecular | 9 |
kapton tape | 9 |
analysis demonstrated | 9 |
side effects | 9 |
th day | 9 |
neutralization mechanism | 9 |
primary target | 9 |
derived peptide | 9 |
antigen production | 9 |
rbd amino | 9 |
high resolution | 9 |
sb bound | 9 |
multiple epitopes | 9 |
humanized neutralizing | 9 |
antigenic determinants | 9 |
highest dilution | 9 |
peptide library | 9 |
emerging coronaviruses | 9 |
protein gene | 9 |
mab binding | 9 |
proximal promoters | 9 |
chemokine receptor | 9 |
rna genome | 9 |
mice expressing | 9 |
evaluated using | 9 |
higher sensor | 9 |
close contact | 9 |
showed higher | 9 |
control wells | 9 |
molecular mechanics | 9 |
low frequencies | 9 |
inhibiting sars | 9 |
blot analysis | 9 |
binding activities | 9 |
induced antibodies | 9 |
functional mimicry | 9 |
findings indicate | 9 |
form hydrogen | 9 |
hubei province | 9 |
real time | 9 |
convalescent serum | 9 |
mediate membrane | 9 |
tnt synthesized | 9 |
neutralising antibodies | 9 |
thrombotic thrombocytopenic | 9 |
structural modeling | 9 |
thermofisher scientific | 9 |
horseshoe bat | 9 |
structural definition | 9 |
recovered covid | 9 |
rbd tip | 9 |
cellular elisa | 9 |
tracking changes | 9 |
emerging microbes | 9 |
rigid body | 9 |
multiple comparison | 9 |
cs cs | 9 |
may result | 9 |
remains unclear | 9 |
mabs targeting | 9 |
expressing sars | 9 |
days following | 9 |
homology models | 9 |
rbd receptor | 9 |
dynamic light | 9 |
spike fusion | 9 |
therapeutic options | 9 |
nanobodies bind | 9 |
filtration chromatography | 9 |
observational cohort | 9 |
cell pools | 9 |
receptor functional | 9 |
cell infection | 9 |
using one | 9 |
ace reveals | 9 |
acid change | 9 |
neutralizing capacity | 9 |
lower levels | 9 |
protein conformation | 9 |
chain interactions | 9 |
antibody therapeutics | 9 |
lung cells | 9 |
dmem supplemented | 9 |
based discovery | 9 |
emerging coronavirus | 9 |
target antigen | 9 |
receptor structural | 9 |
mrna vaccine | 9 |
previous study | 9 |
may serve | 9 |
five patients | 9 |
selection variant | 9 |
ml rbd | 9 |
low ph | 9 |
np assembly | 9 |
nucleotide sequence | 9 |
rbd structures | 9 |
human transgenic | 9 |
see materials | 9 |
three washes | 9 |
neutralized mers | 9 |
maximum likelihood | 9 |
interaction surface | 9 |
lung viral | 9 |
quantitative analysis | 9 |
thrombocytopenic purpura | 9 |
two regions | 9 |
surface spike | 9 |
superdex column | 9 |
genomic sequences | 9 |
human immune | 9 |
human embryonic | 9 |
cultured cells | 9 |
inactivated virus | 9 |
respiratory illness | 9 |
mediating viral | 9 |
neutralization escape | 9 |
sensor sensitivity | 9 |
active sites | 9 |
search models | 9 |
cell tropism | 9 |
plasma cells | 9 |
response current | 9 |
considered significant | 9 |
microscopy data | 9 |
nan doi | 9 |
simplex virus | 9 |
point titer | 9 |
expression level | 9 |
host interaction | 9 |
interface area | 9 |
fc control | 9 |
early stage | 9 |
antibody targeting | 9 |
incubation times | 9 |
unique mutations | 9 |
stably expressing | 9 |
overlapping epitopes | 9 |
ongoing pandemic | 9 |
porcine cov | 9 |
infectious dose | 9 |
cell suspension | 9 |
recent reports | 9 |
better binding | 9 |
rbd conformation | 9 |
four distinct | 9 |
wetting method | 9 |
residues within | 9 |
binds angiotensin | 9 |
host species | 9 |
cov replication | 9 |
asian strains | 9 |
binds ace | 9 |
main hot | 9 |
nl respiratory | 9 |
coronavirus replication | 9 |
generation sequencing | 9 |
nonlinear regression | 9 |
whose alteration | 9 |
cell proteases | 9 |
cellular membranes | 9 |
purified sybodies | 9 |
online version | 9 |
studied using | 9 |
positive bfe | 9 |
significant reduction | 9 |
human body | 9 |
potently inhibits | 9 |
structure refinement | 9 |
galectin fold | 9 |
positively correlated | 9 |
proteins using | 9 |
circulating sars | 9 |
rapidly spread | 9 |
common marmoset | 9 |
based neutralization | 9 |
potent inhibitors | 9 |
light blue | 9 |
display library | 9 |
enzyme active | 9 |
potential covid | 9 |
igg format | 9 |
transfected hek | 9 |
two residues | 9 |
lentiviral particles | 9 |
data demonstrate | 9 |
multiple targets | 9 |
virus envelope | 9 |
mammalian species | 9 |
antibody repertoire | 9 |
infect cells | 9 |
fc fragment | 9 |
assessed using | 9 |
higher igg | 9 |
sulfate proteoglycans | 9 |
fc proteins | 9 |
antibody complexes | 9 |
structural biology | 9 |
cellular cytotoxicity | 9 |
creoptix ag | 9 |
national institutes | 9 |
steered molecular | 9 |
per ml | 9 |
cell subsets | 9 |
rbd ls | 9 |
transmission electron | 9 |
cellular membrane | 9 |
assay buffer | 9 |
soluble decoy | 9 |
camelid antibodies | 9 |
asymptomatic individuals | 9 |
ectodomain trimer | 9 |
yeast display | 9 |
computational design | 9 |
np nb | 9 |
cytokine storm | 9 |
next step | 9 |
applied biosystems | 9 |
inhibit viral | 9 |
emerging infectious | 9 |
ace cryo | 9 |
mm sodium | 9 |
murine antisera | 9 |
reactive protein | 9 |
confirmed sars | 9 |
rbd regions | 9 |
open source | 9 |
experimental validation | 9 |
spike igg | 9 |
terminal residues | 9 |
visual molecular | 9 |
protein purification | 9 |
coronavirus middle | 9 |
induced high | 9 |
closed form | 9 |
favorable interactions | 9 |
robust antibody | 9 |
spearman correlation | 9 |
virus infections | 9 |
virus attachment | 9 |
also bound | 9 |
nunc maxisorp | 9 |
tumor growth | 9 |
single particle | 9 |
experimental data | 9 |
fusion partner | 9 |
neutralisation assay | 9 |
structural comparison | 9 |
bias voltage | 9 |
pichia pastoris | 9 |
vaccination regimes | 9 |
severely ill | 9 |
nanomolar affinity | 9 |
desolvation energy | 9 |
sequence identities | 9 |
two days | 9 |
therapeutic interventions | 9 |
rate constant | 9 |
ug ml | 9 |
monomeric form | 9 |
phage elisa | 9 |
nasal washes | 9 |
replication cycle | 9 |
th response | 9 |
ace competition | 9 |
computational studies | 9 |
also confirmed | 9 |
collectrin domain | 9 |
immune cross | 9 |
blood mononuclear | 9 |
syndrome coronaviruses | 9 |
plasma donation | 9 |
antibodies showed | 9 |
lead contact | 9 |
complex structures | 9 |
glycosylation mutants | 9 |
protective antibodies | 9 |
page gel | 9 |
synthetic nanobody | 9 |
trimerization motif | 9 |
cytokine production | 9 |
potently neutralizing | 9 |
protein residues | 9 |
best models | 9 |
trimeric rbd | 9 |
immunofluorescence assay | 9 |
healthy blood | 9 |
fold decrease | 9 |
studies using | 9 |
early stages | 9 |
immunization groups | 9 |
core structure | 9 |
recombinant soluble | 9 |
atypical pneumonia | 9 |
std nmr | 9 |
acquired thrombotic | 9 |
host membrane | 9 |
elution buffer | 9 |
neutralizing immune | 9 |
also significantly | 9 |
seasonal influenza | 9 |
using clinical | 9 |
transmembrane protease | 9 |
blocks receptor | 9 |
two domains | 8 |
highest binding | 8 |
mice treated | 8 |
sample collection | 8 |
structural data | 8 |
culture collection | 8 |
recovered patient | 8 |
per group | 8 |
receptor engagement | 8 |
column volumes | 8 |
standard error | 8 |
binding properties | 8 |
effective strategy | 8 |
test results | 8 |
competitive elisa | 8 |
rbd site | 8 |
rmsd values | 8 |
vaccine strategies | 8 |
show high | 8 |
fused sdabs | 8 |
hamster model | 8 |
aa variation | 8 |
control proteins | 8 |
molecular evolution | 8 |
prediction matrix | 8 |
individual antibodies | 8 |
viral transmission | 8 |
tyrosine kinase | 8 |
third party | 8 |
patients showed | 8 |
infection assay | 8 |
variable regions | 8 |
postfusion conformation | 8 |
party material | 8 |
antibody avidity | 8 |
gravity flow | 8 |
total number | 8 |
total volume | 8 |
potent inhibitory | 8 |
credit line | 8 |
two patients | 8 |
linked glycan | 8 |
ace inhibitors | 8 |
may contribute | 8 |
mediated membrane | 8 |
potential conflict | 8 |
patients define | 8 |
fab complex | 8 |
detailed protocol | 8 |
may play | 8 |
type culture | 8 |
single clones | 8 |
polyclonal neutralizing | 8 |
first case | 8 |
competing financial | 8 |
viral rbds | 8 |
give appropriate | 8 |
neutralizing abs | 8 |
combat covid | 8 |
unmodified rbd | 8 |
predicted sites | 8 |
hydrophilic residues | 8 |
designing sars | 8 |
genus betacoronavirus | 8 |
permitted use | 8 |
microbes infections | 8 |
draining ln | 8 |
viral spread | 8 |
immune serum | 8 |
luciferase assay | 8 |
like viruses | 8 |
neutralizing epitope | 8 |
truncated version | 8 |
conjugated ag | 8 |
specifically targeting | 8 |
rbd construct | 8 |
ray structure | 8 |
downward rbd | 8 |
signaling pathway | 8 |
fc antibody | 8 |
mononuclear cells | 8 |
sybody libraries | 8 |
distinct conformational | 8 |
ace complexes | 8 |
coronavirus structure | 8 |
appropriate credit | 8 |
inflammatory cytokine | 8 |
animal ace | 8 |
neutralization determinant | 8 |
three libraries | 8 |
hp column | 8 |
potential drugs | 8 |
molar excess | 8 |
indicated otherwise | 8 |
survival rate | 8 |
american type | 8 |
human lung | 8 |
residues whose | 8 |
similar binding | 8 |
hydrophobic interaction | 8 |
broad neutralization | 8 |
cov strain | 8 |
human interaction | 8 |
data collected | 8 |
buffer ph | 8 |
new england | 8 |
core region | 8 |
intended use | 8 |
cattle goat | 8 |
previous sars | 8 |
cell populations | 8 |
highly sensitive | 8 |
synchrotron radiation | 8 |
proximal origin | 8 |
particle cryo | 8 |
fc binding | 8 |
orbital method | 8 |
rbd position | 8 |
two consecutive | 8 |
md trajectories | 8 |
post transfection | 8 |
binding data | 8 |
serum iga | 8 |
circuit board | 8 |
pseudotyped lentivirus | 8 |
unsupervised cryo | 8 |
mutational escape | 8 |
synthetic library | 8 |
studies show | 8 |
analysis software | 8 |
fold reduction | 8 |
complex stability | 8 |
also shown | 8 |
site residues | 8 |
monomer form | 8 |
receptor structure | 8 |
mucosal immune | 8 |
specific total | 8 |
coronavirus strains | 8 |
better understanding | 8 |
disease caused | 8 |
stimulated gene | 8 |
copy numbers | 8 |
commonly used | 8 |
negative charge | 8 |
goat igg | 8 |
studies suggest | 8 |
covid patients | 8 |
inhibits sars | 8 |
protease inhibitors | 8 |
main chain | 8 |
cov susceptible | 8 |
acid sequences | 8 |
bonding interactions | 8 |
dna sequences | 8 |
roc curves | 8 |
surface glycoprotein | 8 |
coronavirus envelope | 8 |
greatly reduced | 8 |
apn ectodomain | 8 |
fold lower | 8 |
express ace | 8 |
rbd containing | 8 |
hydroxyl group | 8 |
well defined | 8 |
vivo half | 8 |
lc ms | 8 |
oropharyngeal saliva | 8 |
guinea pig | 8 |
atomic level | 8 |
multiple organ | 8 |
commun doi | 8 |
expressed sars | 8 |
using rbd | 8 |
possibly due | 8 |
iga titers | 8 |
protein showed | 8 |
reservoir solution | 8 |
crystallographic software | 8 |
clinical improvement | 8 |
written informed | 8 |
computational modeling | 8 |
severe infection | 8 |
mouse fc | 8 |
temporal profiles | 8 |
cov infected | 8 |
antibody therapy | 8 |
different species | 8 |
one amino | 8 |
model building | 8 |
transgenic mouse | 8 |
first identified | 8 |
immunodominant sites | 8 |
block viral | 8 |
florian krammer | 8 |
protease domain | 8 |
modified vaccinia | 8 |
steric clashes | 8 |
spike antigens | 8 |
surrogate virus | 8 |
crude extracts | 8 |
mutation rate | 8 |
entry via | 8 |
international concern | 8 |
viral pathogenesis | 8 |
dependent binding | 8 |
different mechanisms | 8 |
cavity formed | 8 |
antibodies isolated | 8 |
mediated blockage | 8 |
virus lethality | 8 |
high concentrations | 8 |
negative subjects | 8 |
small proportion | 8 |
natural products | 8 |
cr binding | 8 |
mutant rbds | 8 |
permission directly | 8 |
protein variant | 8 |
pbs buffer | 8 |
genomic rna | 8 |
hace interaction | 8 |
week intervals | 8 |
rate constants | 8 |
reporting summary | 8 |
potent germline | 8 |
immunized groups | 8 |
chinese hamster | 8 |
block binding | 8 |
surface receptors | 8 |
rapid spread | 8 |
spike variants | 8 |
control cohort | 8 |
evolutionary rate | 8 |
rbd igm | 8 |
relatively small | 8 |
symptomatic patients | 8 |
salt concentration | 8 |
culture infectious | 8 |
efficient sars | 8 |
past years | 8 |
human host | 8 |
antigenic site | 8 |
sequence conservation | 8 |
health sciences | 8 |
open reading | 8 |
potent pan | 8 |
circulating igg | 8 |
diagnostic tests | 8 |
direct contact | 8 |
therapeutic intervention | 8 |
ternary complex | 8 |
induce high | 8 |
visit http | 8 |
small scale | 8 |
emerged novel | 8 |
spike subunit | 8 |
binding interactions | 8 |
phaser crystallographic | 8 |
genebank id | 8 |
elisa binding | 8 |
lung diseases | 8 |
rbd classes | 8 |
transcription factor | 8 |
rapid unsupervised | 8 |
highly variable | 8 |
neutralization epitope | 8 |
pei max | 8 |
protein prevents | 8 |
dissociation phase | 8 |
time scales | 8 |
terminal end | 8 |
towards sars | 8 |
i fusion | 8 |
dna vaccines | 8 |
intranasal delivery | 8 |
nb i | 8 |
cov recombinant | 8 |
receptor hace | 8 |
negative nii | 8 |
polyacrylamide gel | 8 |
southern biotech | 8 |
developed using | 8 |
od values | 8 |
pbsa calculations | 8 |
ab responses | 8 |
expression medium | 8 |
immunological assessment | 8 |
two sybodies | 8 |
prevent infection | 8 |
betweenness centrality | 8 |
uniform refinement | 8 |
high throughput | 8 |
incubation period | 8 |
severe symptoms | 8 |
epitopes recognized | 8 |
conserved epitope | 8 |
antibody sequences | 8 |
vaccines based | 8 |
asymptomatic sars | 8 |
using molecular | 8 |
bronchitis virus | 8 |
novel angiotensin | 8 |
mediated entry | 8 |
healthy donor | 8 |
nasopharyngeal swab | 8 |
sequence alignments | 8 |
lines indicate | 8 |